Significant Reduction in the Incidence of Non-Coronavirus Infections in Patients with Chronic Lymphocytic Leukemia on Ibrutinib and Venetoclax Treatment During the COVID-19 Pandemic: an Additional Benefit of Lockdown.
Hematological oncology（2023）
Key words
chronic lymphocytic leukemia,ibrutinib,infections,lockdown,out-patient health care visits,pandemic
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined